
Novartis trims its pipeline
Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

Another strike for biotech: China
Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.